Author information:
(1)The Netherlands Cancer Institute, Amsterdam, the Netherlands.
(2)Vall d'Hebron University Hospital and Institute of Oncology (VHIO), 
Universitat Autònoma de Barcelona, Barcelona, Spain.
(3)Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
(4)Princess Margaret Cancer Centre, Toronto, Canada.
(5)West German Cancer Center, University Hospital Essen, University 
Duisburg-Essen, Essen, Germany, and German Cancer Consortium (DKTK), partner 
site University Hospital Essen, Essen, Germany.
(6)National Cancer Center Hospital East, Chiba, Japan.
(7)Institut Claudius Regaud, Toulouse, France.
(8)National Cancer Center Hospital, Tokyo, Japan.
(9)University Medical Center Utrecht, Utrecht, the Netherlands.
(10)Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
(11)Massachusetts General Hospital, Boston, Massachusetts.
(12)Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
(13)Memorial Sloan-Kettering Cancer Center, New York, New York.
(14)Keck School of Medicine at the University of Southern California, Los 
Angeles, California.
(15)UCLA Medical Center, Santa Monica, California.
(16)Novartis Pharmaceutical Corporation, East Hanover, New Jersey.
(17)Novartis Institutes for Biomedical Research, Cambridge, Massachusetts.
(18)Array BioPharma Inc., Boulder, Colorado.
(19)Novartis Pharma AG, Basel, Switzerland.
(20)The Netherlands Cancer Institute, Amsterdam, the Netherlands. 
j.schellens@nki.nl.
(21)Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, 
Utrecht, the Netherlands.